Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled trial of safinamide for cognition in non-demented Parkinson's disease
2010-020109-34Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and confusion comparing Safinamide add-on with Placebo add-on (2 arms). Primary endpoint: Change in PD-CRS total score at 12 weeks. Started Sep 2010; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)confusion
Beyond the preview
Go deeper on 2010-020109-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020109-34.